KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Free Cash Flow (2017 - 2025)

Aquestive Therapeutics has reported Free Cash Flow over the past 9 years, most recently at -$8.0 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$8.0 million for Q4 2025, down 25.24% from a year ago — trailing twelve months through Dec 2025 was -$52.5 million (down 46.45% YoY), and the annual figure for FY2025 was -$52.5 million, down 46.45%.
  • Free Cash Flow for Q4 2025 was -$8.0 million at Aquestive Therapeutics, up from -$12.9 million in the prior quarter.
  • Over the last five years, Free Cash Flow for AQST hit a ceiling of $8.8 million in Q1 2023 and a floor of -$23.5 million in Q1 2025.
  • Median Free Cash Flow over the past 5 years was -$8.0 million (2025), compared with a mean of -$7.0 million.
  • Biggest five-year swings in Free Cash Flow: surged 197.63% in 2022 and later tumbled 378.78% in 2024.
  • Aquestive Therapeutics' Free Cash Flow stood at -$8.6 million in 2021, then surged by 197.63% to $8.4 million in 2022, then crashed by 159.09% to -$5.0 million in 2023, then dropped by 29.55% to -$6.4 million in 2024, then decreased by 25.24% to -$8.0 million in 2025.
  • The last three reported values for Free Cash Flow were -$8.0 million (Q4 2025), -$12.9 million (Q3 2025), and -$8.0 million (Q2 2025) per Business Quant data.